• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Keywords » Vivitrol

Items Tagged with 'Vivitrol'

ARTICLES

Fact Sheet

Naltrexone (ReVia, Vivitrol) Fact Sheet

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder (AUD)—though it is also approved for opioid use disorder (OUD).




Read More
Patient Sheet

Olanzapine (Zyprexa) Fact Sheet for Patients

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Olanzapine is used to treat certain mental/mood conditions such as schizophrenia, bipolar disorder, and depression in combination with other medications.




Read More
Patient Sheet

Naltrexone (ReVia, Vivitrol) Fact Sheet for Patients

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone treats moderate to severe alcohol use disorder.




Read More
Fact Sheet

NALTREXONE (ReVia, Vivitrol) Fact Sheet [G]

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone is the first-line medication for alcohol use disorder (AUD) and is also approved for opioid use disorder (OUD).




Read More
Research Update

A Rapid Initiation Protocol for Long-Acting Injectable Naltrexone for Opioid Use Disorder

April 1, 2025
Noah Capurso, MD, MHS
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD, MHS. Dr. Capurso has no financial relationships with companies related to this material. 

Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.


Read More
Clinical Guidance

How to Discuss and Initiate Extended-Release Naltrexone (Vivitrol)

January 1, 2025
Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release naltrexone injection (XR-NTX) is an effective medication for some patients with opioid use disorder (OUD).




Read More
Fact Sheet

Naltrexone (ReVia, Vivitrol) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder—though it is also approved for opioid use disorder.




Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • supportive psychotherapy Dalle 11082023.jpg
    Psychology and Social Work

    Treating BPD Series, Episode 2: Transference-Focused Psychotherapy—From Splitting to Coherence with Frank Yeomans, MD, PhD

    In this episode, Dr. Frank Yeomans offers a deep dive into the theory and clinical practice of TFP as a treatment for Borderline Personality Disorder.

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.